Abstract:Policy Points The adoption of Medicaid institutions for mental disease (IMD) exclusion waivers increases the likelihood of substance abuse treatment facilities offering mental health and substance abuse treatment for co-occurring disorders, especially in residential facilities. There are differential responses to IMD waivers based on facility ownership. For-profit substance abuse treatment facilities are responsive to the adoption of IMD substance use disorder waivers, whereas private not-for-profit and public entities are not. The response of for-profit facilities suggests that integration of substance abuse and mental health treatment for individuals in residential facilities may be cost-effective. Context: Access to integrated care for those with co-occurring mental health (MH) and substance use disorders (SUDs) has been limited because of an exclusion in Medicaid on paying for SUD care for those in institutions for mental disease (IMDs). Starting in 2015, the federal government encouraged states to pursue waivers of this exclusion, and by the end of 2020, 28 states had done so. It is unclear what impact these waivers have had on the availability of care for co-occurring disorders and the characteristics of any facilities that expanded care because of them. Methods: Using data from the National Survey of Substance Abuse Treatment Services, we estimate a two-stage residual inclusion model including time- and state-fixed effects to examine the effect of state IMD SUD waivers on the percentage of facilities offering co-occurring MH and SUD treatment, overall and for residential facilities specifically. Separate analyses are conducted by facility ownership type. Findings: Results show that the adoption of an IMD SUD waiver is associated with 1.068 greater odds of that state having facilities offering co-occurring MH and substance abuse (SA) treatment a year or more later. The adoption of a waiver increases the odds of a state's residential treatment facility offering co-occurring MH and SA treatment by 1.129 a year or more later. Additionally, the results suggest 1.163 higher odds of offering co-occurring MH/SA treatment in private for-profit SA facilities in states that adopt an IMD SUD waiver while suggesting no significant impact on offered services by private not-for-profit or public facilities. Conclusions: Our study findings suggest that Medicaid IMD waivers are at least somewhat effective at impacting the population targeted by the policy. Importantly, we find that there are differential responses to these IMD waivers based on facility ownership, providing new evidence for the literature on the role of ownership in the provision of health care.

Computing Discrete Logarithms in F36*137 using Magma

Getting What You Pay For: Impact of Copayments on Physical Therapy and Opioid Initiation, Timing, and Continuation for Newly Diagnosed Low Back Pain

Aortofemoral Bypass to Bridge End-Stage Renal Disease Patients with Severe Iliac Calcification to Kidney Transplantation

Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.

Changes in Healthcare Spending Attributable to High Deductible Health Plan Offer Among Enrollees with Comorbid Substance Use Disorder and Cardiovascular Disease

Patient experiences with outpatient opioid use disorder treatment before and during COVID-19: results from a survey of Medicaid members

Zero-Dollar Copayment Impact on Adherence Scores for Centers for Medicare and Medicaid Services Star Ratings Generic Medications

What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan

Why higher copayments for opioids did not reduce use among Medicare beneficiaries

Discharge Against Medical Advice from Hospitalizations for Substance Use Disorders: the Potential Impact of the Affordable Care Act.

Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs

Comparison of Low-Value Care Among Commercial and Medicaid Enrollees

Ontogeny of pulsatile secretion of gonadotropin-releasing hormone in the bull calf during infantile and pubertal development.

Impact of Medication Adherence on Health Services Utilization in Medicaid

The effects of Medicaid policy changes on adults' service use patterns in Kentucky and Idaho

Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus

The Impact of Medicaid Institutions for Mental Disease Exclusion Waivers on the Availability of Substance Abuse Treatment Services and the Varying Effect by Ownership Type

Can telehealth expansion boost health care utilization specifically for patients with substance use disorders relative to patients with other types of chronic disease?

Exploring patient perspectives on the impact of resuming cost sharing: a qualitative analysis

Prompt access to outpatient care post-incarceration among adults with a history of substance use: Predisposing, enabling, and need-based factors

The impact of telehealth cost-sharing on healthcare utilization: Evidence from high-deductible health plans